35.000 people attended the European Society for Medical Oncology (ESMO) Annual Congress, held from 20 to 24 October in Madrid, Spain, where the latest data in oncology research and development was presented. Along with several updates, mostly in solid tumours, different advocacy topics were discussed as part of the Patient Advocacy Track. Myeloma Patients Europe…
Today, 26 October 2023, is World Amyloidosis Day, a day dedicated to raising awareness about the rare disease amyloidosis and the key issues and challenges for patients. A central theme for the day, organised by the Amyloidosis Alliance, alongside amyloidosis patient organisations from across the globe, is improving the diagnosis experience of patients. Amyloidosis is…
Myeloma Patients Europe (MPE) will present as part of the Patient Advocacy Track at the European Society for Medical Oncology (ESMO) Annual Congress. The Congress will be held from 20 to 24 October in Madrid, Spain where the latest data in oncology research and development will be presented. Kate Morgan, MPE Co-Chief Executive Officer, and…
On October 12, 2023, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) gave positive recommendation for the conditional marketing authorisation of elranatamab, also known as Elrexfio. The treatment will be offered as a 40 mg/ml solution for injection. Its active component, elranatamab, is a bispecific monoclonal antibody that…
MPE and our community are extremely saddened by the ongoing and devastating events in Israel and Gaza. The death of hundreds of innocent people is completely unacceptable, and our deepest sympathy goes out to everyone affected. We know our members are continuing to provide support to patients and their families during this difficult time. All…
Today is European Myeloma Day, a date to raise awareness about the most important issues for European myeloma patients. The findings of a recent report developed by Myeloma Patients Europe (MPE) are the driving reason for early diagnosis to be the focus of European Myeloma Day this year. By raising awareness of myeloma and disseminating…
Myeloma Patients Europe (MPE) is attending the International Myeloma Society (IMS) Annual Meeting in Athens, Greece, from 27 – 30 September. This year, the IMS meeting corresponds with European Myeloma Day, allowing us to engage with the whole myeloma community to mark this important event. The IMS Annual Meeting brings together myeloma experts from…
On September 15, 2023, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has recommended non-renewal of marketing authorisation for belamaf mafadotin (Blenrep®). Blenrep is currently approved for myeloma patients who have received at least four previous treatments and have stopped responding to at least one proteasome inhibitor…
